(Reuters) - NEW YORK - Drugmakers Merck & Co. and Schering-Plough Corp. reported second-quarter results that handily topped Wall Street expectations on Monday, helped by increased sales of the cholesterol-lowering drugs they co-market and other medicines.
Merck, whose results were also spurred by soaring vaccine sales, really gave investors something to cheer about when it boosted its 2007 earnings forecast 25 cents per share and significantly raised the outlook for sales of several of its drugs, sending its stock up more than 8 percent.
Read more at Reuters.com Business News
Merck, whose results were also spurred by soaring vaccine sales, really gave investors something to cheer about when it boosted its 2007 earnings forecast 25 cents per share and significantly raised the outlook for sales of several of its drugs, sending its stock up more than 8 percent.
Read more at Reuters.com Business News
No comments:
Post a Comment